



ACMT Position Statement: Buprenorphine Administration in the Emergency Department

Paul M. Wax¹ · Andrew I. Stolbach² · Evan S. Schwarz³ · Brandon J. Warrick⁴ · Timothy J. Wiegand⁵ · Lewis S. Nelson⁶

Received: 11 April 2019 / Accepted: 15 April 2019 / Published online: 13 May 2019
© American College of Medical Toxicology 2019

Keywords Buprenorphine · Opioid use disorder · Emergency department · Opioid agonist therapy · MAT (medication-assisted therapy)

The position of the American College of Medical Toxicology (ACMT), endorsed by the American Academy of Emergency Medicine (AAEM) and the American College of Emergency Physicians (ACEP), is as follows:

ACMT supports the administration of buprenorphine in the emergency department (ED) as a bridge to long-term addiction treatment.

Furthermore, ACMT supports the administration of buprenorphine to appropriate patients in the ED to treat opioid withdrawal and to reduce the risk of opioid overdose and death following discharge.

Background

In response to escalating opioid-related ED visits and fatalities across the nation, there is a pressing need for the expansion of treatment and recovery opportunities for patients suffering from the consequences of long-term opioid use, which include dependence, abuse, hyperalgesia, and addiction [1, 2].

Within the healthcare community, it is widely agreed that opioid use disorder (OUD) is a chronic disease with medical and social components and that the best practice for management

of OUD includes opioid agonist therapy (OAT) [3]. OAT uses evidence-based approaches with either buprenorphine or methadone to allow patients to minimize the use of illicit opioids, prevent overdose, and improve overall health and functioning. For most patients, providing an initial dose of buprenorphine (also called initiation or induction) can be easily and safely performed in the ED or on an outpatient basis, with close follow-up or a “warm hand-off” with a long-term treatment provider. OAT is generally supplemented with other long-term supportive measures such as group- and community-based or intensive outpatient programs. Although methadone and naltrexone are also used for addiction treatment, this statement focuses on buprenorphine due to its safety profile and ability to be both administered in and prescribed from the ED. Methadone may be administered to patients already managed in opioid treatment programs that use methadone but may not be prescribed for addiction treatment.

Buprenorphine in the ED

Buprenorphine (in combination with naloxone in the outpatient setting) has been utilized for nearly 20 years in an office-

Supervising Editor: Mark B. Mycyk, MD

✉ Paul M. Wax
positionstatements@acmt.net

¹ University of Texas Southwestern, Dallas, TX, USA

² Johns Hopkins University School of Medicine, Baltimore, MD, USA

³ Division of Emergency Medicine, Washington University School of Medicine, Saint Louis, MO, USA

⁴ University of New Mexico, Albuquerque, NM, USA

⁵ University of Rochester Medical Center, Rochester, NY, USA

⁶ Rutgers New Jersey Medical School, Newark, NJ, USA

or clinic-based setting that allows for either observed or home initiation of therapy [4]. Providing an initial dose of buprenorphine during an ED visit after an overdose, or during an ED visit for opioid withdrawal, for OUD improves success in engagement of patients into medication-assisted therapy (MAT, also called medication for addiction treatment) [5–7]. Furthermore, in the USA, any licensed prescriber of controlled substances can administer a dose of buprenorphine in the hospital/ED daily for up to 3 days, if desired [8]. (Outpatient prescription requires a Drug Addiction Treatment Act of 2000 “X-waiver” on their DEA controlled substance registration [9].) Outpatient prescription may help patients avoid return ED visits during the bridge period to a long-term treatment program.

The ED can play a crucial role in the lives of patients with OUD and their families by offering treatment with buprenorphine. Such treatment needs to be supported by prompt access to ongoing treatment with buprenorphine. There are several reasons for this:

- The ED sees a large number of patients presenting with opioid overdose, opioid withdrawal, or OUD.
- For many patients at high-risk for overdose, the ED is their primary access point to health care and treatment.
- Evaluation in the ED represents an opportunity to engage patients in a discussion of OAT and harm reduction strategies to mitigate risk from the continued use of illicit drugs after discharge.
- Following initiation of buprenorphine in the ED, a bridge clinic or “warm handoff” to a treatment provider will improve engagement into long-term treatment.
- Screening for OUD in patients who present to the ED for other medical reasons provides an important opportunity to begin intervention immediately for those who screen positive.
- Buprenorphine is relatively safe even in high doses and has a substantially lower abuse potential than full agonist opioids [10].

ACMT supports the administration of buprenorphine in the ED as a bridge to long-term addiction treatment, and ACMT supports the administration of buprenorphine to ED patients to treat opioid withdrawal and to reduce the risk of opioid overdose and death following discharge.

Funding Information None

Compliance with Ethical Standard

Conflict of Interest None

Disclaimer While individual practices may differ, this is the position of the American College of Medical Toxicology (ACMT) at the time written, after a review of the issue and pertinent literature.

References

1. Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2017. *NCHS Data Brief*. 2018;329:1–8.
2. Vivolo-Kantor AM, Seth P, Gladden RM, et al. Vital signs: trends in emergency department visits for suspected opioid overdoses - United States, July 2016–September 2017. *MMWR Morb Mortal Wkly Rep*. 2018;67(9):279–85.
3. Kresina TF, Lubran R. Improving public health through access to and utilization of medication assisted treatment. *Int J Environ Res Public Health*. 2011;8(10):4102–17.
4. Martin SA, Chido LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. *Ann Intern Med*. 2018;169(9):628–35.
5. D’Onofrio G, McCormack RP, Hawk K. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. *JAMA*. 2015;313(16):1636–44.
6. D’Onofrio G, McCormack RP, Hawk K. Emergency departments - A 24/7/365 Option for Combating the Opioid Crisis. *N Engl J Med*. 2018;379(26):2487–90.
7. Love JS, Perrone J, Nelson LS. Should buprenorphine be administered to patients with opioid withdrawal in the emergency department? *Ann Emerg Med*. 2018;72(1):26–8.
8. Substance Abuse and Mental Health Services Administration. Special circumstances for providing buprenorphine. www.samhsa.gov/medication-assisted-treatment/legislation-regulations-guidelines/special-circumstances-providing-buprenorphine. Accessed 11 Dec 2018.
9. Substance Abuse and Mental Health Services Administration. Qualify for a physician waiver. www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management/qualify-for-physician-waiver. Accessed 11 Dec 2018.
10. Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency department with buprenorphine. *Ann Emerg Med*. 2019;73(5):481–7.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.